Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous melanoma: baseline and ongoing laboratory evaluation.

Claus Garbe1

  • 1Division of Dermato-Oncology, Department of Dermatology, University of Tübingen, Germany. claus.garbe@med.uni-tuebingen.de

Dermatologic Therapy
|November 22, 2005
PubMed
Summary

Physicians should carefully select diagnostic tests for cutaneous melanoma to balance utility and patient anxiety. For high-risk melanoma, lymph node ultrasound and S-100beta protein monitoring are common follow-up tools.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.

British journal of cancer·2026
Same author

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal for immunotherapy of cancer·2026
Same author

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Area of Science:

  • Oncology
  • Dermatology
  • Medical Imaging

Background:

  • Cutaneous melanoma diagnosis involves various tests, but risks like cost and anxiety necessitate careful consideration of their utility.
  • Current practices in Germany often include lymph node ultrasound for detecting metastasis after primary melanoma diagnosis.

Purpose of the Study:

  • To critically evaluate the usefulness and feasibility of diagnostic and imaging methods for cutaneous melanoma.
  • To guide the selection of appropriate follow-up examinations based on melanoma recurrence risk.

Main Methods:

  • Review of diagnostic and imaging techniques for cutaneous melanoma.
  • Analysis of current follow-up protocols in Germany, including lymph node ultrasound and S-100beta protein levels.
  • Evaluation of whole-body imaging utility in detecting metastasis.

Related Experiment Videos

Main Results:

  • Physical examination is sufficient for low-risk melanoma follow-up (≤1 mm thickness).
  • For intermediate/high-risk melanoma (>1 mm thickness), lymph node ultrasound and S-100beta protein are frequently used.
  • Whole-body imaging is beneficial for patients with locoregional or distant metastasis, aiding in surgical resection considerations for Stage IV disease.

Conclusions:

  • Diagnostic test selection for cutaneous melanoma requires balancing benefits against risks like cost and patient anxiety.
  • Follow-up strategies should be risk-stratified, utilizing specific tests like ultrasound and tumor markers for higher-risk patients.
  • Advanced imaging like PET-CT and whole-body MRI can identify resectable disease in advanced melanoma stages.